Recent clinical trials have focused on innovative eye drop treatments for dry eye disease, particularly in the context of autoimmune disorders. Here are five notable trials:
- PL9643 in the MELODY-1 Phase 3 Study: Palatin Technologies conducted a Phase 3 trial of PL9643, showcasing its potential as a leading treatment for moderate to severe dry eye disease (DED). The trial highlighted PL9643’s broad efficacy across multiple signs and symptoms of DED, along with excellent safety and tolerability, distinguishing it from current treatments (Ophthalmology Times).
- SHR8028 Eye Drops: Conducted by Jiangsu HengRui Medicine Co., this Phase 3 trial assessed the efficacy, safety, and tolerability of SHR8028 eye drops compared to a vehicle (placebo) in treating DED. The trial aimed to provide significant data on improving symptoms like corneal staining and eye dryness (Home – ClinicalTrials.gov).
- ST-100 by Stuart Therapeutics: In a Phase 2 clinical trial, ST-100 was tested for its effectiveness in treating DED. The trial emphasized its novel approach to resolving inflammation and improving ocular health, with promising results that pave the way for further development (Stuart Therapeutics). Clinical trial is one of the Ophthalmic Trial Australia projects.
- Perfluorohexyloctane Eye Drops: A trial focusing on patients with DED associated with Meibomian gland dysfunction explored the efficacy of perfluorohexyloctane eye drops. It demonstrated superior improvements in symptoms such as corneal staining and dryness compared to controls, suggesting a viable new treatment option (Ophthalmology Times).
- Amniotic Membrane Extract: A study investigated the therapeutic effects of an amniotic membrane extract in severe cases of DED. This innovative approach aims to harness the natural healing properties of amniotic material to improve symptoms in patients with severe DED (Ophthalmology Times).
These trials represent a diverse array of approaches, from receptor-specific treatments and anti-inflammatory agents to novel extracts and advanced formulations, all aimed at improving symptoms and quality of life for patients suffering from dry eye associated with autoimmune conditions. The team at Ophthalmic Trials Australia are involved in these and other trials with promising success for patients with autoimmune disease and dry eye.
A Multicenter, Randomized, Controlled, Double Masked, Phase 2 Trial of the Safety and Therapeutic Effects of ILYX-002 Versus Vehicle Control for Treatment of Dry-Eye Disease in Patients with Autoimmune Disease also run at Ophthalmic Trials Australia also shows promise.
The post Latest Dry Eye Trials for Autoimmune Disease appeared first on Mark Hinds.
